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OBJECTIVE—To evaluate the incidence and relative risk of type 2 diabetes deﬁned by the
newly proposed HbA1c diagnostic criteria in groups categorized by different baseline HbA1c
levels.
RESEARCH DESIGN AND METHODS—Using data from the European Prospective
Investigation of Cancer (EPIC)-Norfolk cohort with repeat HbA1c measurements, we estimated
the prevalence of known and previously undiagnosed diabetes at baseline (baseline HbA1c
$6.5%) and the incidence of diabetes over 3 years. We also examined the incidence and corre-
sponding odds ratios (ORs) by different levels of baseline HbA1c. Incident diabetes was deﬁned
clinically (self-report at follow-up, prescribed diabetes medication, or inclusion on a diabetes
register) or biochemically (HbA1c $6.5% at the second health assessment), or both.
RESULTS—The overall prevalence of diabetes was 4.7%; 41% of prevalent cases were pre-
viouslyundiagnosed.Among5,735participantswithoutdiabetesatbaseline(identiﬁedclinically
orusingHbA1ccriteria,orboth),72developeddiabetesover3years(1.3%[95%CI1.0–1.5]),of
which 49% were identiﬁed using the HbA1c criteria. In 6% of the total population, the baseline
HbA1c was 6.0–6.4%; 36% of incident cases arose in this group. The incidence of diabetes in
this group was 15 times higher than in those with a baseline HbA1c of ,5.0% (OR 15.5 [95% CI
7.2–33.3]).
CONCLUSIONS—The cumulative incidence of diabetes deﬁned using a newly proposed
HbA1c threshold in this middle-aged British cohort was 1.3% over 3 years. Targeting interven-
tions to individuals with an HbA1c of 6.0–6.4% might represent a feasible preventive strategy,
although complementary population-based preventive strategies are also needed to reduce the
growing burden of diabetes.
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T
ype 2 diabetes is a major public
health concern worldwide. An esti-
mated 439 million people will have
the disease by 2030 (1). It is possible to
halve the incidence of type 2 diabetes
among individuals at high risk through
lifestyle and pharmacologic interventions
(2–4 ) .H o w e v e r ,i ti su n l i k e l yt h a tp o p u -
lation screening for impaired glucose tol-
erance using anoralglucose tolerancetest
(OGTT) is a feasible method of identify-
ing those at high risk in clinical practice
(5) because it is time- and resource-
consuming and has poor reproducibility
(6). If a measure of blood glucose were to
be used to deﬁne the risk of developing
diabetes,thenitwouldseemlogicaltouse
the same test for diagnosis and informing
treatment decisions (7).
Glycated hemoglobin (HbA1c) is a re-
liable measure of long-term glycemic ex-
posure (8) that correlates well with the
risk of microvascular and macrovascular
complications of diabetes (9,10). It does
not necessitate fasting or timed blood
samples. Previous concerns regarding
the standardization of assays have largely
been resolved (11). Consequently, the
American Diabetes Association (ADA) re-
cently recommended that HbA1c be in-
cluded as a diagnostic test for diabetes,
withadiagnosticthresholdof$6.5%(12).
To better estimate the burden of the
disease and potential beneﬁts of preven-
tive interventions, it is necessary to have
accurate data on incidence. Reported
estimates of incidence in adult popula-
tions have varied considerably, from 2 to
25per1,000person-years(13–16).How-
ever, many of the studies were restricted
to high-risk populations (13) and deﬁned
diabetes using a clinical rather than a bio-
chemical diagnosis (14). Fewer studies
have investigated the incidence of diabe-
tes based on longitudinal repeat blood
glucose measurements in population-
basedsamples(15,16),andnonehaveex-
amineddiabetes incidence using repeated
measures of HbA1c.
In this study we estimated the prev-
alence and incidence of diabetes deﬁned
using the newly proposedHbA1ccutoffof
6.5% in a population-based British co-
hort. To inform the choice of appropriate
HbA1c thresholds to identify individuals
at high risk to whom preventive interven-
tions might be offered, we used data on
longitudinal repeat HbA1c values at base-
line and after 3 years of follow-up to ex-
amine the incidence and relative risk of
clinically diagnosed diabetes and diabetes
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ORIGINAL ARTICLEdeﬁned using HbA1c diagnostic criteria in
groups deﬁned by different baseline
HbA1c values.
RESEARCH DESIGN AND
METHODS
Study design and population
The European Prospective Investigation
of Cancer (EPIC)-Norfolk is a population-
based prospective study that monitors
25,639 men and women aged 40–74 years
residing in the Norfolk region, U.K. De-
tails of the study have been described
elsewhere (17). In brief, between 1993
and 1997, 77,630 individuals were re-
cruited from general practice to partici-
pate in the study, and 25,639 (33%)
consentedandattendedabaselinehealth
assessment.
Participants completed question-
naires about their personal and family
history of disease, medication, and life-
style factors, including smoking habits.
They were asked whether a physician had
ever told them that they had any of the
conditionsin alist thatincludeddiabetes,
heart attack, and stroke. Baseline diabetes
status was ascertained by 1) self-report of
diabetes medication, 2) diabetes medica-
tion brought to the baseline examination,
3) participants indicating modiﬁcation of
their diet in the past year because of diabe-
tes, or 4) participants indicating adherence
to a diabetic diet. Anthropometric and
blood pressure measurements, as well as
nonfasting blood samples were taken at
the health assessment.
Because funding for measurement of
HbA1c only became available in 1995,
about 50% of all participants had infor-
mationonthismeasureatbaseline.HbA1c
w a sm e a s u r e do nf r e s hE D T Ab l o o d
samples using high-performance liquid
chromatography (Diamat Automated
Glycated Hemoglobin Analyzer; Bio-Rad
LaboratoriesLtd., HemelHemstead, U.K.),
which was standardized to the Diabetes
Control and Complications Trial (DCCT)
assay.
Participants were invited to attend a
second health assessment after 3 years
(1998–2001), at which identicalmeasure-
mentsweretaken,and15,028participants
(59%) attended. General practitioners of
participants whose HbA1c test results ex-
ceeded $7.0% were notiﬁed so that they
couldassumeresponsibilityforconﬁrming
diagnosis and arranging treatment. The
studywasapprovedbytheNorwichDistrict
Health Authority Ethics Committee. All
participants gave signed informed consent.
Individuals who live the Norfolk area
are slightly healthier than those in the
general U.K. population, with a standard-
ized mortality ratio of 93 (Ofﬁce for Na-
tional Statistics death registration data,
2008). However, EPIC-Norfolk partici-
pants are similar to a nationally represen-
tative sample regarding anthropometric
indices, blood pressure, and serum lipid
levels (17).
We report results for follow-up at the
second health assessment, a median of 3
years. We limited our analyses to the
6,372 individuals with HbA1c measure-
mentsatbaselineandatthesecondhealth
assessment. We used this study sample to
estimate the prevalence of known (clini-
cally diagnosed diabetes, self-reported
physician-diagnosed diabetes, and diabe-
tes medication) and previously undiag-
nosed diabetes at baseline (baseline
HbA1c $6.5%). After excluding those
with diabetes at baseline (clinically diag-
noseddiabetesanddiabetesdeﬁnedusing
HbA1c diagnostic criteria), we further ex-
cluded 335 individuals with missing data
for other metabolic risk factors, including
age, sex, a family history of diabetes,
smoking, the use of corticosteroids and
antihypertensive drugs, BMI, waist cir-
cumference, systolic blood pressure, cho-
lesterol, and triglyceride, leaving 5,735
individuals for analyses of the incidence
and risk of diabetes (Fig. 1).
Ascertainment of incident diabetes
Participants were identiﬁed as having
incident diabetes if 1)t h e yr e p o r t e d
physician-diagnosed diabetes or diabetes
medication, or brought diabetes medica-
tion to the second health assessment
(clinical diagnosis), 2)t h e yw e r ei d e n t i -
ﬁed on medical records, diabetes registers,
or death certiﬁcates (clinical diagnosis) or
3)t h e yh a da nH b A 1c of $6.5% at the
second health assessment (HbA1c-deﬁned
diabetes). Participants were identiﬁed
through their general practice diabetes
register or the Norfolk and Norwich Hos-
pital diabetes register. Participants admit-
ted to a hospital with a diabetes-related
condition were identiﬁed by their National
Health Service number. Hospitals were
linked to the East Norfolk Health Author-
ity database, which identiﬁes all hospital
contacts throughout England and Wales
for Norfolk residents. Vital status for all
EPIC-Norfolk participants was obtained
through death certiﬁcation at the Ofﬁce
for National Statistics, and death certiﬁca-
tion with coding for diabetes was identi-
ﬁed. Previous validation studies in this
cohort using capture–recapture analysis
indicated that the use of multiple sources
ofascertainmentinformationfordiabetes
detected 99% of incident cases when
comparing with diagnostic information
from a comprehensive review of medical
records (18).
Statistical analyses
In 5,735 participants free of diabetes at
baseline with data on HbA1c for the base-
line and second health assessments, we
calculated the incidence of diabetes de-
ﬁned clinically and by using HbA1c diag-
nostic criteria in the whole cohort and
separately for different categories of base-
line HbA1c. Baseline characteristics were
summarized for groups deﬁned by differ-
ent categories of baseline HbA1c (,5.0,
5.0–5.4, 5.5–5.9, and 6.0–6.4%). We
tested for differences between groups us-
ing the x
2 test for categoric variables and
ANOVA or Kruskal-Wallis tests for nor-
mally or nonnormally distributed contin-
uous variables, respectively.
We used logistic regression to esti-
mate the risk of developing diabetes as
measured by the odds ratios (ORs) for
every 0.5% increase in HbA1c as well as
for different categories of HbA1c com-
pared with the lowest HbA1c category of
,5.0%. We examined ORs adjusted for
ageonly,ageandsexonly,andmultiplerisk
factors, including age, sex, self-reported
family history of diabetes, smoking, the
use of antihypertensive drugs or cor-
ticosteroids, BMI, waist circumference,
systolic blood pressure, and total choles-
terol, HDL cholesterol, and triglyceride
values. To inform alternative screening
strategies, we investigated risk factors as-
sociated with incident diabetes in those
with a baseline HbA1c of ,6.0%.
We also performed a sensitivity anal-
ysis using a more restricted deﬁnition of
incident diabetes in which participants
were not classiﬁed as having incident
diabetes unless a self-reported diagnosis
wassupportedbyinformationondiabetes-
speciﬁc medication or conﬁrmed by in-
formation from clinical records, death
certiﬁcates, or HbA1c.
RESULTS—Table 1 summarizes base-
line characteristics of participants in the
EPIC-Norfolk cohort by different HbA1c
categories. Participants (45% men) had a
mean age of 57.4 (SD 9.4) years. Partici-
pants with a higher HbA1c value were
older, more likely to be male, obese, cur-
rent smokers, and to come from a lower
socioeconomic class than those with a
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Chamnan and Associateslower HbA1c value. They were also more
likely to have higher blood pressure,
higher total cholesterol and triglyceride
values,andlowerHDLcholesterolvalues.
There was no difference in family history
of diabetes and the use of corticosteroids
among the groups.
Prevalence of diabetes at baseline
Among 6,372 individuals with HbA1c
measurements at both health assess-
ments,302 (4.7%)had prevalentdiabetes
at baseline (Fig. 1). Among these individ-
uals, 178 (2.8%) had known diabetes
(those identiﬁed clinically), and 124
(1.9%) had previously undiagnosed diabe-
tes (those identiﬁed using HbA1c criteria).
Incidence of diabetes over 3 years
Among 5,735participantsfreeofdiabetes
at baseline, 72 developed diabetes over
3years(Fig.1).Thecumulativeincidence
w a s1 . 3 %( 9 5 %C I1 . 0 –1.5) over 3 years,
an annual incidence of 0.4%. Among
these new cases of diabetes, 37 individu-
als (51%) were identiﬁed clinically (e.g.,
by their response to the questionnaire at
the second health check or through link-
agetoclinicalrecordsordiabetesregisters),
with an incidence of 0.6% (0.4–0.9). The
remaining 35 individuals (49%) with inci-
dentdiabeteswereidentiﬁedbytheirHbA1c
results at the second health assessment.
Risk of developing diabetes in groups
deﬁned by different HbA1c levels
Table 2 reports the incidence of diabetes
by baseline HbA1c levels for clinical diag-
nosis only and for clinical or HbA1c-
deﬁned diagnosis, or both. The incidence
of diabetes increased progressively with
increasing baseline HbA1c levels. In those
with a baseline HbA1c of 6.0–6.4%, the
incidence of clinically diagnosed or
HbA1c-deﬁned diabetes was three times
higher than that of clinically diagnosed
diabetes, at 7.0 (95% CI 4.8–10.1) and
2.4 (1.3–4.6), respectively. Thirty-six
percent of incident cases of diabetes arose
from individuals with a baseline HbA1c of
6.0–6.4% (6% of the total population),
and just over 35% of incident cases arose
among individuals with a baseline HbA1c
of ,5.5% (69% of the total population).
Signiﬁcant positive associations were
found between HbA1c and the risk of de-
veloping diabetes (Table 2). A 0.5% in-
crease in baseline HbA1c was associated
with more than a twofold increase in the
risk of clinically diagnosed or HbA1c-
deﬁned diabetes, or both (age-adjusted
OR 2.7 [95% CI 2.1–3.5]). Participants
with a baseline HbA1c of 6.0–6.4% had
about a sevenfold higher risk of clini-
cally diagnosed diabetes than those with
an HbA1c of ,5.0%. The highest risk of
clinically diagnosed or HbA1c-deﬁned di-
abetes was observed in the highest base-
line HbA1c category compared with those
withabaselineHbA1cof,5.0%(OR15.5
[7.2–33.3]). These ORs remained un-
changed after adjustment for other risk
factors.
Among individuals with a baseline
HbA1c ,6.0%, a family history of diabe-
tes and waist circumference were the
strongest nonlaboratory predictors of in-
cident diabetes over 3 years.
Figure 1—Schematic diagram demonstrates the numbers and percentages of individuals with prevalent and incidence diabetes in a cohort of 6,372
menandwomenover3years.IndividualswithclinicallydiagnoseddiabetesandHbA1c$6.5%wereconsideredtohaveclinicallydiagnoseddiabetes
inthisdiagram.*Self-reporteddiabetes,evidenceofdiabetesmedications,anddietarymodiﬁcationduetodiabetes.†Self-reporteddiabetes,evidence
of diabetes medication, diabetes registers, hospitalizations with diabetes, and diabetes codes on death certiﬁcates.
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HbA1c-deﬁned incidence of diabetesIn the sensitivity analysis using a
more restricted deﬁnition of incident di-
abetes, 59 individuals developed diabetes
(Supplementary Table 1). The incidence
was1.0(95%CI0.8–1.3)over 3years,an
annual incidence of 0.3%. Incident cases
in 37 individuals (63%) were identiﬁed
using HbA1c diagnostic criteria. Approxi-
mately 40% of incident cases of diabetes
developedinindividualswithahighbase-
line HbA1c of 6.0–6.4% (6% of total pop-
ulation). A 27-fold higher risk of diabetes
was observed in those with a baseline
HbA1c of 6.0–6.4% compared with those
with a baseline HbA1c of ,5.0%.
CONCLUSIONS—We used data
from a large population-based British
prospective cohort to estimate the preva-
lence and incidence of diabetes deﬁned
clinically or by HbA1c,o rb o t h ,o v e r3
years. The HbA1c diagnostic threshold of
6.5% identiﬁed 50% of new cases. The
incidence of diabetes increased progres-
sively across baseline HbA1c levels, with
36%ofincidentcasesdevelopinginindivid-
u a l sw i t hab a s e l i n eH b A 1c of 6.0–6.4%.
To the best of our knowledge, this
study is the ﬁrst to report the incidence of
diabetes based on HbA1c diagnostic crite-
ria using repeated assessment of HbA1c.
Our prevalence estimate is comparable
with the prevalence of diabetes in England
(4.4%) estimated from an epidemiologic
model in which individuals with known
and previously undiagnosed diabetes
were included (19). We also found that
approximately 40% of prevalent cases
were identiﬁed using HbA1c diagnostic
criteria and, hence, were previously un-
diagnosed. This is consistent with previ-
ousstudiesusinganOGTTasascreening
test (20).
A number of studies have estimated
diabetes incidence by using longitudinal
repeat OGTT or fasting plasma glucose
measurements (15,16). The incidence of
diabetes in these studies varied from 6 to
10% over9 to10years. Data froma British
population in Ely, Cambridgeshire,
showed that the cumulative incidence of
diabetes using repeat OGTT measure-
ments was 5.9% over 10 years, corre-
sponding to an annual incidence of 0.6%
(16). This is comparable with the low an-
nual incidence of 0.4% in the current
study. The higher incidence in the earlier
study may be explained by enhanced case
detection from repeated testing by OGTT
over a longer period (OGTT testing at
baseline, 4.5, and 10 years in the earlier
Ely study vs. HbA1c at baseline and after 3
years of follow-up in the EPIC-Norfolk
study) and the different contributions of
the“healthyvolunteereffect”ineachstudy
(response rates of 74% in the Ely study
and 33% in the EPIC-Norfolk study).
Few studies have examined the in-
cidence and relative risk of diabetes in
individuals or groups deﬁned by different
baseline HbA1c levels. Selvin et al. (21)
examined the incidence of self-reported
diabetes in American men and women
with different baseline HbA1c values.
The 15-year cumulative incidence of
diabetes was 6, 12, 21, and 44% in indi-
viduals with an HbA1c of ,5.0, 5.0–5.4,
5.5–5.9, and 6.0–6.4%, respectively.
The estimated annual incidence was higher
than those observed across all HbA1c
categories in our study. This might be
explained by the differences in levels
of other risk factors (higher BMI, smok-
ing,andfamilyhistoryofdiabetesinthe
Selvin study), follow-up time (15 vs. 3
years, if incidence rates are not con-
sistent across different durations of
Table 1—Comparison of baseline characteristics across categories of baseline HbA1c in 5,735 participants in the EPIC-Norfolk cohort
Variable Total
HbA1c level P for
difference* ,5.0% 5.0–5.4% 5.5–5.9% 6.0–6.4%
N (%) 5,735 (100) 1,849 (32.2) 2,119 (36.9) 1,397 (24.4) 370 (6.5)
Age (years) 57.4 (9.4) 54.1 (9.2) 57.4 (9.1) 60.3 (8.7) 62.4 (8.2) ,0.001
Men, n (%) 2,481 (43.3) 746 (40.4) 932 (44.0) 634 (45.4) 169 (45.7) 0.016
Social class,† n (%) ,0.001
Class I–IIIa 3,694 (64.4) 1,255 (67.9) 1,358 (64.1) 861 (61.6) 220 (59.5)
Class IIIb–V 2,041 (35.6) 594 (32.1) 761 (35.9) 536 (38.4) 150 (40.5)
Current smokers, n (%) 525 (9.2) 141 (7.6) 165 (7.8) 165 (11.8) 54 (14.6) ,0.001
Family history of diabetes, n (%) 697 (12.2) 217 (11.7) 250 (11.8) 177 (12.7) 53 (14.3) 0.469
Medication use, n (%)
Corticosteroids 156 (2.7) 44 (2.4) 61 (2.9) 37 (2.7) 14 (3.8) 0.454
Antihypertensive drugs 811 (14.1) 188 (10.2) 301 (14.2) 243 (17.4) 79 (21.4) ,0.001
BMI (kg/m
2) 25.9 (3.7) 25.4 (3.5) 25.9 (3.6) 26.3 (3.8) 26.6 (4.0) ,0.001
BMI category, n (%) ,0.001
,25 kg/m
2 2,528 (44.1) 935 (50.6) 906 (42.8) 553 (39.6) 134 (36.2)
25–29.9 kg/m
2 25,24 (44.0) 738 (39.9) 956 (45.1) 657 (47.0) 173 (46.8)
$30 kg/m
2 683 (11.9) 176 (9.5) 257 (12.1) 187 (13.4) 63 (17.0)
Waist circumference, cm 86.9 (12.2) 84.8 (12.2) 87.1 (11.9) 88.6 (11.9) 90.0 (13.0) ,0.001
Systolic blood pressure, mmHg 133.4 (17.5) 130.6 (17.1) 133.4 (17.1) 135.7 (18.1) 138.9 (17.3) ,0.001
Diastolic blood pressure, mmHg 82.0 (10.8) 80.9 (10.6) 82.1 (10.8) 82.9 (11.1) 84.1 (10.9) ,0.001
Total cholesterol, mmol/L 6.1 (1.1) 5.8 (1.1) 6.1 (1.1) 6.3 (1.1) 6.4 (1.2) ,0.001
HDL cholesterol, mmol/L 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4) 1.4 (0.4) 0.001
TG, median (IQR), mmol/L 1.4 (1.0–2.1) 1.3 (0.9–1.8) 1.5 (1.0–2.1) 1.6 (1.1–2.2) 1.7 (1.2–2.5) ,0.001
Data are presented as the mean (SD), unless speciﬁed otherwise. IQR, interquartile range; TG, triglyceride. *Differences between groups using x
2 tests for categoric
variables, and ANOVA or Kruskal-Wallis tests for normally or nonnormally distributed continuous variables. †Registrar General’s Social Class: class I = professional,
etc. occupations; II = managerial and technical occupations; IIIa = skilled occupations (nonmanual); IIIb = skilled occupations (manual); IV = partly-skilled occu-
pations; V = unskilled occupations.
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ent deﬁn i t i o n so fd i a b e t e su s e di ne a c h
study.
HbA1c has been shown to be a useful
tool for the early detection of diabetes
(21). A few studies have demonstrated
that HbA1cpredictsfuture riskofdiabetes
in high-risk individuals with glucose in-
t o l e r a n c e( 2 2 ) .W eh a v es h o w nt h a t
HbA1c predicts risk of diabetes in healthy
middle-aged men and women. An HbA1c
of 6.0–6.4% identiﬁed 24% of clinically
incident diabetes, and 36% of clinically
incident or HbA1c-deﬁned diabetes.
These ﬁgures were even higher when a
more restricted deﬁnition of incident di-
abetes was used. Recent evidence shows
that this predictive ability also holds true
in low-risk nondiabetic men and women
(21)andinelderlyindividuals(23).How-
ever, given that the associations between
HbA1c and the risk of diabetes were
hardly changed after adjustment for mul-
tiple risk factors, there may not be much
to gain from including data on multiple
risk factors alongside HbA1c for predic-
tion of diabetes risk.
ADA suggested that there was no
speciﬁc threshold that deﬁnes individuals
who might be offered preventive inter-
ventions and that any such threshold
would vary between countries with dif-
ferentheathcarepriorities(12).However,
ADA suggested that individuals with
an HbA1c between 6.0 and 6.4% might
represent a group in whom the risk of
development of diabetes was very high
and who could therefore be targeted for
individual prevention interventions
(12). ADA also suggested that this range
should not be considered an absolute
threshold and that interventions may be
appropriate in other individuals on the
basis of other risk information. Our ﬁnd-
ings support this statement by demon-
strating that most new cases of diabetes
developed in those with a baseline HbA1c
of ,6.0%.
The selection of a population for a
high-risk prevention strategy is by the
level of risk identiﬁed, the proportion of
the population to be targeted, and the
proportion of future cases that might
therefore be prevented. Our study
showed that 36% of new cases of diabetes
arosefromthe6%ofthestudypopulation
who had the highest glycemic levels
(HbA1c 6.0–6.4%). Indeed, if previously
proven intensive prevention interven-
tions (2,3) were targeted at this middle-
aged population, approximately 20% of
new cases of diabetes could be prevented
over 3 years. Strategies for identifying
which individuals should have an HbA1c
measurement, including simple risk
scores using easily measured or routinely
available risk factors, are needed.
Although the category of people with
an HbA1c of 6.0–6.4% identiﬁes a high-
riskgroup,most newcasesofdiabetesde-
veloped in individuals whose baseline
HbA1c values were ,6%. Complementary
strategies to identify high-risk individ-
uals among those without raised HbA1c
may therefore be necessary. Our sub-
group analysis in individuals with an
HbA1c of ,6.0% suggested that those
with central obesity and a family history
of diabetes might represent another rela-
tively easily identiﬁable subgroup to
whom preventive interventions could be
targeted. This also suggests that in addi-
tion to high-risk approaches, we need to
develop a complementary population-
basedstrategyaimedatshiftingthewhole
distribution of HbA1c in the population
to reduce the risk of both diabetes and
its complications (24). However, al-
though there is some evidence for the
cost-effectiveness of preventioninterven-
tions among high risk individuals (25),
evidenceonthecost-effectivenessofpop-
ulation-based strategies is very limited,
making judgments about the balance of
investment in high-risk and population-
based approaches difﬁcult.
We have reported the incidence of
diabetes in a large prospective British co-
hort using clinical ascertainment and
newly proposed HbA1c diagnostic criteria.
Participants included in this analysis were
healthier than those excluded; hence, our
ﬁndingsarelikelytounderestimatethein-
cidence of diabetes in the whole cohort.
Given the 33% recruitment rate in this
study,itispossiblethatparticipantsmight
be more health-conscious and more likely
to engage in healthy behaviors and to take
Table 2—Incidence and risk (OR) of diabetes over 3 years by baseline HbA1c categories in the EPIC-Norfolk cohort (N = 5,735)
Variable Total
HbA1c level P for
trend ,5.0% 5.0–5.4% 5.5–5.9% 6.0–6.4%
Clinically diagnosed diabetes
N (% of total participants) 5,735 1,849 (32) 2,119 (37) 1,397 (24) 370 (6) —
Incident cases (% of total cases) 37 7 (19) 6 (16) 15 (41) 9 (24) —
Three-year cumulative incidence, % 0.6 (0.4–0.9) 0.4 (0.2–0.8) 0.3 (0.1–0.6) 1.1 (0.6–1.8) 2.4 (1.3–4.6) —
Unadjusted OR 1.0 0.7 (0.3–2.2) 2.9 (1.2–7.0) 6.6 (2.4–17.7) ,0.001
Age-adjusted OR 1.0 0.8 (0.3–2.4) 3.3 (1.3–8.4) 8.0 (2.8–22.7) ,0.001
Age- and sex-adjusted OR 1.0 0.8 (0.3–2.4) 3.3 (1.3–8.3) 7.9 (2.8–22.4) ,0.001
Multivariable-adjusted OR* 1.0 0.8 (0.3–2.3) 3.0 (1.2–7.8) 6.8 (2.3–20.1) ,0.001
Clinically diagnosed and/or
HbA1c-deﬁned diabetes
N (% of total participants) 5,735 1,849 (32) 2,119 (37) 1,397 (24) 370 (6) —
Incident cases (% of total cases) 72 9 (13) 16 (22) 21 (29) 26 (36) —
Three-year cumulative incidence, % 1.3 (1.0–1.5) 0.5 (0.3–0.9) 0.8 (0.5–1.2) 1.5 (1.0–2.3) 7.0 (4.8–10.1) —
Unadjusted OR 1.0 1.6 (0.7–3.5) 3.1 (1.4–6.8) 15.5 (7.2–33.3) ,0.001
Age-adjusted OR 1.0 1.6 (0.7–3.8) 3.5 (1.6–7.8) 18.0 (8.1–40.0) ,0.001
Age- and sex-adjusted OR 1.0 1.6 (0.7–3.7) 3.4 (1.5–7.7) 17.7 (8.0–39.5) ,0.001
Multivariable-adjusted OR* 1.0 1.6 (0.7–3.6) 3.3 (1.5–7.4) 15.6 (6.9–35.7) ,0.001
*Adjusted for age, sex, social class, self-reported family history of diabetes, smoking, use of corticosteroids and antihypertensive drugs, BMI, waist circumference,
systolic blood pressure, cholesterol, HDL cholesterol, and triglyceride.
954 DIABETES CARE, VOLUME 34, APRIL 2011 care.diabetesjournals.org
HbA1c-deﬁned incidence of diabetesup existing preventive services compared
with nonparticipants. We might therefore
haveunderestimatedthe overall incidence
ofdiabetesinthepopulation,whichmight
consequently inﬂuence estimates of the
relative risk for HbA1c.
Because the EPIC-Norfolk study col-
lected nonfasting blood samples, it is not
possible to compare the predictive ability
forincidentdiabetesofdifferentmeasures
of glycemia. Similar to other diagnostic
tests, the use of a single measure of HbA1c
for diagnosing diabetes might lead to
some degree of misclassiﬁcation. How-
ever, given that HbA1c is more reliable
compared with an OGTT and the fasting
plasma glucose test, the misclassiﬁcation
is likely to be only modest. A relatively
short follow-up period and relatively
small number of events mean that our
ﬁnding should be interpreted with cau-
tion. However, our study is one of the
largest incidence studies reported.
Furthermore,thefollow-upof3years
is still a plausible and important time-
frame for identifying those at high risk of
diabetes,becauseinadditiontolong-term
risk information, one might also be in-
terested in and more persuaded for be-
havior modiﬁcation by information on
the short-term risk of diabetes. Our ﬁnd-
ings were speciﬁc to a population aged
40–74 years, and may not represent the
burden and risk of diabetes in relation to
HbA1c levels in younger people. Lastly,
most of the EPIC-Norfolk participants
are of European descent, which limits
the generalizability of our ﬁndings to
other ethnic groups and populations.
In conclusion, the cumulative inci-
dence of diabetes deﬁned using a newly
proposedHbA1cthresholdinthismiddle-
aged British cohort was 1.3% over 3 years
(0.4% per year). HbA1c independently
predicted the risk of incident diabetes,
with each 0.5% difference in HbA1cbeing
associatedwithmorethandoublingofthe
risk of diabetes. Because 36% of incident
cases of diabetes came from the 6% of
the population with a baseline HbA1c of
between6and6.5%,thismaybeaneasily
identiﬁable subgroup to whom pre-
ventive interventions could be targeted.
Alternative strategies to identify high-risk
individuals may be necessary, however,
and complementary population-based
approaches need to be developed to shift
the underlying distribution of glycemia.
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